United Therapeutics Q2 2026 revenues decline 2% to $783.3M
Total revenues slipped 2% in Q2 2026 to $783.3 million, while net income rose 8% to $333.0 million. The company highlighted record Tyvaso DPI growth and two NDAs submitted for ralinepag and Nebulized Tyvaso in IPF.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day